Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Lymphoma
Do we need to continue dose escalations wtih DA REPOCH after a negative interim PET scan for PMBCL?
Related Questions
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
How do you approach patient with CLL/SLL limited to the prostate?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
In light of data from TRIANGLE, ECHO and ENRICH, what is the best strategy to treat newly diagnosed patients w/ blasted variant MCL.
How would you approach a patient with lymphoma (i.e. DLBCL) who has developed chylous pleural effusions while on therapy?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?
How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
